So what with HCV drug when VRTX is curing most patients in US, EU, Japan and many other coutries by next 2 years. VRTX will beat GILD on oral kind too. But I admire GILD for spending $11 B for acquisition so it can cure patients for free in China, India and Africa.
Gilds PSI 7977 hepc polymerase inhibitor, is a blockbuster. Vertex(Incivek) therapy has an under 79% clear (cure) rate after 24 weeks. The side effects are worse then the old standard of care. Many patients have had to stop therapy. This protease inhibitor will soon fall by the wayside or be sent for free to China, India, etc. If you check w/hepc support groups around the country you will find that those you can wait are waiting for 7977. In clinical studys 7977 has close to 100% clear(cure) rate in a shorter period of treatment time w/no side effects. Vertex has already made billions off of an inferior therapy and has barely put a dent in the potential market.This will be a cash cow for Gild.